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IgA1 glycosylation in IgA 
nephropathy: As sweet as it can be
JW Eijgenraam1 and C van Kooten1
Abnormally O-glycosylated IgA1 is likely to be involved in the 
pathogenesis of IgA nephropathy (IgAN). Buck et al. show that the 
enzyme activity and gene expression of specific glycosyltransferases, 
in purified B cells isolated from peripheral blood and bone marrow, 
is not reduced in IgAN patients. As only a small fraction of IgA in 
IgAN patients is abnormally glycosylated, it is probable that a more 
detailed molecular analysis at the single cell level is required to 
unravel the cause of this abnormality.
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The pathogenesis of IgA nephropathy 
(IgAN) is still not clear, but it is now 
well accepted that an aberrant glyco-
sylation pattern of IgA is involved. This 
is supported by the fact that in IgAN, 
mesangial deposits of IgA contain high 
concentrations of abnormally O-gly-
cosylated IgA1, characterized by under-
galactosylation. Buck et al.1 (this issue) 
investigated whether this aberrant glyco-
sylation pattern of IgA in IgAN patients 
is due to diminished activity or reduced 
gene expression of speciﬁc glycosyltrans-
ferases. They investigated the activity 
of the enzyme β-galactosyltransferase 
(C1Gal-T1) and its molecular chaper-
one (Cosmc) in puriﬁed B cells isolated 
from peripheral blood and bone marrow 
of IgAN patients and controls. They also 
measured gene expression in peripheral 
blood and bone marrow cells and related 
this to the enzyme GalNAc-T2, which 
synthesizes the core O-glycan. Using this 
approach, no diﬀerences in O-galactosy-
lation activity between IgAN patients 
and controls could be detected.
IgAN is a heterogeneous disease with 
a wide range in clinical presentations, 
varying from asymptomatic micro-
scopic hematuria to gross macroscopic 
hematuria, and can have a variable 
clinical outcome ranging from normal 
glomerular ﬁltration rate to end-stage 
renal disease in up to 30% of cases. The 
histological hallmark of the disease is 
the presence of mesangial deposition 
of polymeric IgA1, in combination with 
complement factor C3 and often IgG or 
IgM. In IgAN patients, the serum con-
centration of IgA is frequently increased 
compared with that in controls, but in 
addition, IgA present in the circulation 
was shown to be abnormally O-glyco-
sylated. Importantly, this undergalac-
tosylated form of the IgA1 hinge region 
was also overrepresented in biopsies 
of patients with IgAN.2 Therefore, it is 
likely that this abnormally glycosylated 
IgA is involved in the pathogenesis 
of IgAN. The reduced galactosylation 
leads to increased exposure of the inter-
nal GalNAc (Tn antigen) that can be 
detected with speciﬁc lectins. Recently 
it has been suggested to use this speciﬁc 
characteristic for the development of a 
diagnostic test based on enzyme-linked 
immunosorbent assay in IgAN.3 This 
abnormal glycosylated IgA has a higher 
tendency to self-aggregate and form 
complexes with IgG antibodies directed 
against epitopes in the hinge region of 
IgA1. Besides, in patients with Henoch-
Schönlein purpura, a disease closely 
related to IgAN with a similar renal 
histological pattern, only those patients 
who had abnormal glycosylated IgA had 
renal involvement, whereas patients with 
normal glycosylated IgA did not have 
renal involvement.4
Despite the importance of aber-
rantly glycosylated IgA in IgAN, the 
molecular mechanisms underlying 
these diﬀerences are not known. With 
the identification and characteriza-
tion of the enzyme system responsible 
for O-linked glycosylation, including 
C1Gal-T1 and its molecular chaperone 
Cosmc, novel avenues of research have 
opened up. However, an important and 
intriguing observation is that aberrant 
O-glycosylation seems to be absent in 
other serum proteins, whereas even for 
IgA it is generally accepted that only a 
small proportion of the IgA molecules 
show these alterations (Figure 1). For 
instance, GalNAc-speciﬁc lectins speciﬁ-
cally react with high-molecular weight 
fractions of serum IgA, which constitute 
only 10% of circulating IgA.5
Since IgA1 glycosylation is determined 
within B lymphocytes, and only a frac-
tion of the IgA1 seems to be affected, 
this suggests that alterations in glyco-
sylation are present in only a subset of 
B cells. In humans, besides IgA the only 
other immunoglobulin that is O-glyco-
sylated is IgD. Smith et al. have studied 
the glycosylation patterns of IgA1 and 
IgD in IgAN patients and in controls and 
observed that the abnormal underglyco-
sylated pattern of IgA1 was not present 
in IgD.6 As IgD is a marker of naive 
B cells, this might suggest that deﬁciencies 
are restricted to certain diﬀerentiation 
stages of B cells. In the study of Buck et 
al.,1 enzyme activities were determined 
in puriﬁed B cells isolated by positive 
selection using anti-CD19-coated mag-
netic beads. As plasma cells are CD19 
negative, this analysis might exclude the 
contribution of plasma cells. Although 
the number of plasma cells in the circu-
lation will be low, in bone marrow their 
number is expected to be higher. It is 
thought that IgA present in the circula-
tion is produced mainly by plasma cells 
derived from the bone marrow, suggest-
ing that the absence of plasma cells in the 
analysis could be of importance.
The fact that the proposed deﬁcien-
cies are present in only a subset of B cells 
(Figure 1) might suggest that genetic 
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factors are not likely to be involved. 
Nevertheless, it was recently shown that 
polymorphisms in the gene for C1Gal-T1 
were associated with susceptibility for 
the development of IgAN in a Chinese 
population.7 A disease in which aber-
rant glycosylation patterns are present 
due to genetically determined factors is 
the so-called Tn syndrome. This is a rare 
autoimmune disorder in which a somatic 
mutation in the Cosmc gene leads to 
incompletely glycosylated proteins in 
sub-populations of all cell lineages.8 It 
is unclear whether such a mosaic pattern 
can contribute to the aberrant glycosyla-
tion in IgAN, and so far no correlation 
between IgAN and the Tn syndrome has 
been described.
IgA present in the circulation is 
derived not only from the bone marrow, 
but also from mucosal tissues. Interest-
ingly, most IgA produced at the mucosa 
will be dimeric in nature and can either 
be transported over epithelial barriers to 
generate secretory IgA or contributes to 
the high-molecular weight IgA fraction 
in the circulation. Therefore, both high-
molecular weight IgA and secretory IgA, 
which can also be present in the circula-
tion and in renal deposits,9 might repre-
sent a recent mucosal challenge. Buck et 
al.1 investigated the activity of C1Gal-T1 
and Cosmc and GalNAc-T2 in periph-
eral blood and bone marrow samples 
taken from IgAN persons who had no 
macroscopic hematuria or intercurrent 
illness at the time of sampling. This sug-
gests that no active immune reaction 
was present at the time of investigation, 
which might have masked a diﬀerence in 
glycosylation activity.
In a recent vaccination study, a direct 
comparison of glycosylation has been 
made of IgA directed against a mucosal 
antigen, Helicobacter pylori, and against 
a systemic adjusted antigen, tetanus 
toxoid.10 Both in IgAN patients and 
in controls, the IgA1 against H. pylori 
showed higher lectin binding, reflect-
ing more undergalactosylated IgA than 
the IgA against tetanus toxoid. This 
strongly suggests that an aberrant gly-
cosylation pattern in IgAN could not 
only be the result of an intrinsic defect 
in glycosylation mechanisms but also 
might reflect differences in regulation 
of glycosylation (Figure 1). As immu-
noglobulin production is the result of a 
complex process, involving B cells, T cells, 
antigen-presenting cells, and local and 
systemic factors such as cytokines, each 
of these factors can potentially inﬂuence 
the glycosylation proﬁle. Dendritic cells 
are professional antigen-presenting cells 
that have direct eﬀects on B cells and, 
under the inﬂuence of the mucosal envi-
ronment, can promote the generation of 
IgA-producing cells.11 We have shown 
a reduced capacity of dendritic cells of 
IgAN patients to induce IgA switching.12 
Whether the abnormal dendritic-cell 
function also aﬀects the glycosylation pat-
tern in IgAN patients is so far unknown.
In conclusion, it is clear that aberrantly 
glycosylated IgA plays an important role 
in the pathogenesis of IgAN. Glycosyla-
tion is a complex process, inﬂuenced by 
many factors, that can either be intrinsic 
or can diﬀer in time and change because 
of locally determined circumstances. 
The study of Buck et al.1 shows that 
overall there is no difference between 
IgAN patients and controls in C1Gal-T1 
and Cosmc activity nor in gene expres-
sion related to GalNAc-T2. Although 
this study’s results might appear to be 
negative, it clearly brings IgAN research 
to the next level. It is conceivable that 
more detailed molecular analysis will 
be required to unravel the mechanisms 
contributing to undergalactosylation 
of IgA1. This should probably include 
developments in the direction of single-
cell analysis of IgA-producing B cells or 
longitudinal analysis of actively develop-
ing IgA immune responses upon mucosal 
or systemic challenges.
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Figure 1 | Schematic view of potential mechanisms leading to aberrantly glycosylated 
IgA. Undergalactosylated IgA1 is present in serum and biopsies of patients with IgA 
nephropathy (IgAN). This glycosylation is controlled during the synthesis of IgA in B cells by the 
glycosyltransferases C1Gal-T1, its molecular chaperone Cosmc, and GalNAc-T2. As other proteins 
seem not to be affected and only some of the B cells in IgAN produce undergalactosylated IgA, 
generalized intrinsic defects in B cells or other cells can be excluded. Therefore, it is postulated that 
either the glycosylation is disturbed intrinsically in some B cells, or regulatory processes affect only 
some B cells during an ongoing immune response. In the latter case, environmental or cellular 
signals involved in B-cell activation and IgA production might be involved.
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The dynamics of kidney 
donation: Viewpoints from the 
donor, the recipients, and the 
transplant team
A Maiorano1 and FP Schena1
Living kidney transplantation has become increasingly widespread 
to reduce organ shortage. Very few studies have prospectively 
investigated the donor’s long-term risks.  Living donation is a 
complex medical decision in which different actors are involved. This 
therapeutic option needs educational programs for potential donors, 
recipients, and transplant professionals to make them aware of the 
possible risks and benefits.  It is important to fully exploit living-
donor kidney transplantation.
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The ﬁrst successful living-donor kidney 
transplant was performed about 50 years 
ago. Since then, living kidney transplan-
tation has become increasingly wide-
spread1 and has helped reduce organ 
shortage. The advantages of living- 
versus cadaveric-donor transplantation 
are now readily apparent, as the former 
is associated with a shorter time to 
transplantation and results in a better 
long-term graft and patient survival.2
Although rates of living kidney trans-
plantation are increasing worldwide, in 
some areas it still lags behind. There are 
several likely reasons for this: restrictive 
laws, negative attitudes toward living 
donation, lack of organization, and local 
practice. Although many guidelines 
for living-donor evaluation have been 
produced, at the present, very few stud-
ies have prospectively investigated 
the long-term risks to living kidney 
donors.3 In fact, although we know for 
certain that the major short-term risk 
for living donors is low, the long-term 
risk of kidney failure and cardiovascular 
disease is less clear. The cardiovascular 
risk, in particular, needs further atten-
tion in the light of recent population-
based observations that even a small 
reduction in kidney function results in 
a signiﬁcant increase in cardiovascular 
morbidity and mortality.4 Virtually all 
of the studies focusing on the long-term 
outcomes in donors are retrospective, 
many with incomplete follow-up, and 
therefore these studies could be subject 
to selection bias that may signiﬁcantly 
limit their interpretability. Most stud-
ies are underpowered to detect clinically 
meaningful diﬀerences between donors 
and control groups. Many studies com-
pare donors with the general popula-
tion, but donors are screened to be 
healthier than the general population, 
and this may not be a valid comparison 
group. Diﬃculties in measurement of 
blood pressure and renal function may 
underestimate the impact of donation 
on these outcomes. Several studies have 
identiﬁed possible risk factors for devel-
opment of hypertension, proteinuria, 
and end-stage renal disease, but poten-
tial vulnerability factors in donors have 
not been well explored, and there is a 
paucity of data on cardiovascular risk 
factors in donors. Moreover, medical 
exclusion criteria are probably diﬀerent 
between diﬀerent centers, and this may 
also aﬀect outcome.5 Thus, living kidney 
donation is a complex medical decision 
in which several aspects should be dis-
cussed by three diﬀerent players around 
a circular and not a rectangular table 
(Figure 1). We consider this very impor-
tant from a psychological point of view, 
because every player must assume equal 
responsibility in the decision-making 
process. The interaction between the 
three groups is complex: the donor’s 
physician needs to protect the patient; 
the donor wishes to see his or her loved 
one healthy again but may be afraid of 
surgery; and the patient wishes to come 
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